Valuation: Relay Therapeutics, Inc.

Market Cap 3.87B 3.38B 3.11B 2.9B 5.49B 368B 5.58B 37.39B 14.49B 181B 14.53B 14.22B 623B P/E 2026 *
-11.6x
P/E 2027 * -11.3x
Enterprise Value 3.58B 3.13B 2.87B 2.68B 5.08B 341B 5.16B 34.57B 13.4B 167B 13.44B 13.14B 576B EV / Sales 2026 *
285x
EV / Sales 2027 * 224x
Free-Float
93.62%
Yield 2026 *
-
Yield 2027 * -
1 day+0.56%
1 week+0.73%
Current month-4.01%
1 month+14.39%
3 months+43.22%
6 months+119.56%
Current year+112.29%
1 week 17.62
Extreme 17.62
19.93
1 month 12.92
Extreme 12.925
19.93
Current year 7.01
Extreme 7.01
19.93
1 year 3.02
Extreme 3.025
19.93
3 years 1.78
Extreme 1.775
19.93
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 2017-02-28
Director of Finance/CFO 49 2018-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 2015-05-03
Director/Board Member 66 2016-06-30
Director/Board Member 52 2017-02-28
Date Insider Type Main position Quantity % Market Cap.
06-21Fiscal year

Chief Technology Officer

280,368 0.1463%
06-21Sell

Chief Financial Officer

-526,055 0.2746%
06-08Free

Director

32,947 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
+0.56%+0.73%+398.89%+41.86% 3.87B
+0.36%+5.10%+1.04%+6.65% 48.62B
-1.32%+3.72%+396.92%+588.80% 39.86B
+1.84%+11.13%+25.83%-6.28% 33.91B
+1.23%+7.57%+21.23%+63.78% 32.32B
+1.20%+2.26%+15.60%+32.43% 24.73B
+0.25%+2.57% - - 16.63B
+2.89%+8.12%+72.43%+135.18% 15.52B
+0.99%+1.26%+13.98%+18.72% 13.63B
-1.53%+7.67%+14.91%-28.69% 13.41B
Average +0.66%+6.76%+106.76%+94.72% 24.25B
Weighted average by Cap. +0.63%+7.58%+92.44%+126.51%

Financials

2026 *2027 *
Net sales 12.55M 10.97M 10.07M 9.39M 17.81M 1.2B 18.11M 121M 47.01M 586M 47.14M 46.12M 2.02B 16.32M 14.26M 13.1M 12.21M 23.15M 1.55B 23.54M 158M 61.11M 762M 61.29M 59.95M 2.63B
Net income -288M -252M -231M -216M -409M -27.44B -416M -2.78B -1.08B -13.46B -1.08B -1.06B -46.38B -303M -265M -243M -227M -430M -28.89B -438M -2.93B -1.14B -14.17B -1.14B -1.11B -48.82B
Net Debt -292M -255M -234M -219M -414M -27.8B -421M -2.82B -1.09B -13.64B -1.1B -1.07B -46.99B -221M -193M -177M -165M -313M -21.03B -319M -2.13B -827M -10.31B -829M -811M -35.54B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
26-07-02 US$17.96 +1.10% 837,330
26-07-01 US$17.76 -5.08% 3,360,805
26-06-30 US$18.71 -5.22% 5,799,149
26-06-29 US$19.74 +6.36% 4,215,703
26-06-26 US$18.56 +4.09% 12,573,933
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
17.76USD
Average target price
24.82USD
Spread / Average Target
+39.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock